Animale


Receive HTML?

Home arrow Veterinari arrow Combination Vaccine Protects Monkeys from Ebola And Marburg Viruses
Combination Vaccine Protects Monkeys from Ebola And Marburg Viruses PDF Imprimare E-mail

 

 An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys.
"VLPs are one of the most promising candidates for protecting humans against Ebola and Marburg virus infections," says Dr. Kelly Warfield, a researcher at USAMRIID who presented the study. They could also be safer than other vaccine candidates.

Traditionally vaccines against viral diseases have consisted of whole viruses, either the one that causes the disease in a weakened or dead state (like the polio vaccine) or a genetically similar virus that does not usually cause disease but elicits a protective immune response. The problem with this approach is there is the risk, however small, of viral reactivation and infection.

"Since the VLP vaccine does not use a whole virus, there is no chance of infection," says Warfield, who notes that some VLP-based vaccines, such as the human papillomavirus (HPV) vaccine, are already on the market.

To create the vaccine, Warfield and her colleagues infected insect cells with specially engineered baculoviruses. The infected cells then produced VLPs for either Marburg or Ebola, depending on the baculovirus, which were then purified. They mixed the two together and vaccinated the monkeys with it.

"Following challenge with Ebola or Marburg virus, all the VLP-vaccinated monkeys survived challenge without clinical or laboratory signs of infection, while the control animals succumbed to the infection," says Warfield. "Based on their safety profile, immunogenicity and protective efficacy, the VLPs are a leading candidate for use as a filovirus vaccine in humans."

Additionally, Warfield discovered that vaccination with one strain of Marburg VLP produced protection against 3 different strains of the virus, which is surprising. Subunit vaccines (in which only part of the virus is used) had previously not been thought to confer broad-based immunity.

Researchers are currently working on scaling up the production process and hope to begin clinical trials in humans in a few years.

Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) report their results Feb. 26 at the 2008 ASM Biodefense and Emerging Diseases Research Meeting in Baltimore, MD.

Adapted from materials provided by American Society for Microbiology.

American Society for Microbiology (2008, February 27). Combination Vaccine Protects Monkeys From Ebola And Marburg Viruses. ScienceDaily. Retrieved March 3, 2008, from http://www.sciencedaily.com/releases/2008/02/080226135434.htm 

Comments
Cautare
Doar utilizatorii inregistrati pot scrie comentarii.!

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

 
< Precedent   Urmator >

Stiri

Check This out

 Plant Ecology and Evolution Lab 

Citeste mai departe...
 
IUCN study confirms vertebrate extinction crisis
Citeste mai departe...
 
We (G.A.I.N.) have created an English language  homepage.....
Citeste mai departe...
 
The new EAZA campaign is now underway.......
Citeste mai departe...
 

The story of SHAPE―Regionals

Citeste mai departe...
 
Training materials wanted for Romanian project.....
Citeste mai departe...
 
© 2018 Zoolinx Romania

Powered by Pret-Corect